An initial experience with therapeutic drug monitoring of levetiracetam as reported from a pediatric clinical setting in India

Neurology India

Volumn 60, Issue 2, 2012, Pages 146-149

  Mathew, B S ^a   Fleming, D H ^a   Thomas, M ^a   Prabha, R ^a   Saravanakumar, K ^a  

^a CHRISTIAN MEDICAL COLLEGE   (India)

Author keywords

Co medication; concentration; levetiracetam; seizure control

Indexed keywords

CARBAMAZEPINE; ETIRACETAM; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; VALPROIC ACID;

ADOLESCENT; ARTICLE; CHILD; CONTROLLED STUDY; CORRELATIONAL STUDY; DRUG BLOOD LEVEL; DRUG MONITORING; ENZYME INDUCTION; EPILEPSY; HUMAN; INDIA; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PEDIATRIC HOSPITAL; POLYPHARMACY; PRESCHOOL CHILD; SCHOOL CHILD; TERTIARY HEALTH CARE; TREATMENT RESPONSE;

ADOLESCENT; ANTICONVULSANTS; CHILD; CHILD, PRESCHOOL; DRUG MONITORING; EPILEPSY; HUMANS; INDIA; INFANT; PATIENT COMPLIANCE; PIRACETAM;

EID: 84861670578     PISSN: 00283886     EISSN: 19984022     Source Type: Journal    
DOI: 10.4103/0028-3886.96382     Document Type: Article

References (15)

1. Steinhoff BJ, Somerville ER, Van Paesschen W, Rylvin P, Schelstraete I. The SKATE study: An open label community based study of levetiracetam as add on therapy for adults with uncontrolled partial epilepsy. Epilepsy Res 2007;76:6-14. (Pubitemid 47243697)
2. Kwan P, Lim SH, Chinvarun Y, Cabral-Lim L, Aziz ZA, Lo YK, et al. Efficacy and safety of levetiracetam as adjunctive therapy in adult patient with uncontrolled partial epilepsy. Epilepsy Behav 2010;18:100-5.
3. Bootsma HP, Ricker L, Diepman L, Gehring J, Hulsman J, Lambrechts D, et al. Levetiracetam in clinical practice: Long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center. Epilepsy Behav 2007;10:296-303. (Pubitemid 46432220)
4. Glauser TA, Ayala R, Elterman RD, Mitchell WG, Van Orman CB, Gauer LJ, et al. Double-blind placebo controlled trial of adjunctive levetiracetam in pediatric partial seizures. Neurology 2006;66:1654-60. (Pubitemid 43964617)
5. Patsalos PN. Pharmacokinetic profile of levetiracetam: Toward ideal characteristics. Pharmacol Ther 2000;85:77-85. (Pubitemid 30069478)
6. Patsalos PN. The pharmacokinetic characteristics of levetiracetam. Methods Find Exp Clin Pharmacol 2003;25:123-9. (Pubitemid 36406972)
7. Radtke RA. Pharmacokinetics of levetiracetam. Epilepsia 2001;42(SUPPL. 4):24-7. (Pubitemid 32802083)
8. Perucca E, Gidal BE, Baltes E. Effects of comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. Epilepsy Res 2003;53:47-56. (Pubitemid 36170170)
9. Freitas-Limaa P, Alexandre V Jr., Pereira LR, Feletti F, Peruccac E, Sakamotoa CA. Influence of enzyme inducing antiepileptic drugs on the pharmacokinetics of levetiracetam in patients with epilepsy. Epilepsy Res 2011;94:117-20.
10. Lancelin F, Franchon E, Kraoul L, Garciau I, Brovedani S, Tabaouti, K, et al. Therapeutic drug monitoring of Levetiracetam by high performance liquid chromatography with photodiode array ultraviolet detection: Preliminary observations on correlations between plasma concentration and clinical response in patients with refractory epilepsy. Ther drug Monit 2007;29:576-83. (Pubitemid 47494055)
11. Johannessen SI, Battino D, Berry DJ, Bialer M, Kramer G, Tomson T, et al. Therapeutic drug monitoring of the newer antiepileptic drugs. Ther drug Monit 2003;25:347-63. (Pubitemid 36638181)
12. Perruca E. Is there a role for therapeutic drug monitoring of new anticonvulsants? Clin Pharmacokinet 2000;38:191-204.
13. Giroux PC, Salas-Prato M , Theoret Y, Carmant L. Levetiracetam in children with refractory epilepsy: Lack of correlation between plasma concentration and efficacy. Seizure 2009;18:559-63.
14. Gallentine WB, Hunnicutt AS, Husain AM. Levetiracetam in children with refractory status epilepticus. Epilepsy Behav 2009;14:215-8.
15. May TW, Rambeck B, Jurgens U. Serum concentration of levetiracetam in epileptic patients: the influence of dose and comedicaiton. Ther Drug Monit 2003;25:690-9. (Pubitemid 37499303)